Biote Q3 revenue $51.4M (+12.8% YoY); EPS $0.33; Adj. EBITDA $16.2M

biote Corp.

2024-Q3 EPS reported -$0.02 revenue$147,357,000

Revenue of $51.4M, up 12.8% YoY; procedure revenue $37.9M.
Gross profit margin 70.5%, up from 64.5% a year ago on vertical integration savings.
Net income $12.7M ($0.33 diluted EPS) vs. $19.6M ($0.24) in Q3 2023.
Adjusted EBITDA $16.2M, margin 31.5%; grew 15.4% YoY.
Launched proprietary clinical decision support software in September 2024 to strengthen competitive position.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.